The length of stay and inpatient burden in inpatients with different psoriasis subtypes

Abstract

Background: Heavy disease burden of psoriasis has been indicated by previous studies. However, the cost of care and length of stay (LOS) in inpatients with different psoriasis subtypes were rarely addressed. This study aimed to investigate the cost of care and LOS in Chinese patients with different psoriasis types and to clarify the independent factors affecting LOS. Methods: We conducted a cross-sectional study by enrolling patients with psoriasis who were hospitalized between 13 Feb 2017 and 29 Mar 2021. Demographic and clinical characteristics of the patients were collected by reviewing their Electronic Medical Records. Multivariate linear regression was used to estimate the associations with adjustments. Results: A total of 310 adult patients with psoriasis were included (mean cost of care: 13.0±22.3 kCNY; mean LOS: 7.9±4.3 days). Statistically significant differences were found among patients with different psoriasis subtypes in LOS (P<0.001) but not in the cost of care (P=0.530). Relative to psoriasis vulgaris, pustular psoriasis (Adjusted coefficient: 2.37, 95% confidence interval (CI): 0.87-3.87) and erythrodermic psoriasis (Adjusted coefficient: 2.92, 95%CI: 1.38-4.47) were significantly associated with an increased LOS. Meanwhile, respiratory tract infections (Adjusted coefficient: 1.60, 95%CI: 0.11-3.10) also significantly increased the LOS. On the contrary, a decreased LOS was found in psoriatic arthritis patients treated with TNF-alpha inhibitors (Adjusted coefficient: -2.21, 95%CI: -4.37 to -0.05). Conclusions: LOS differed significantly among different psoriasis subtypes while the inpatient burden for a single hospitalization was alike. Infection is an important factor associated with a longer LOS. TNF-alpha inhibitors evidently reduced the total hospital stay period for patients with psoriatic arthritis.

Clinical characteristics and heterogeneity of generalized pustular psoriasis: A comparative study in a large retrospective cohort

“…GPP is distinct from PV and represents a severer disease with activated autoinflammatory response. Historically, GPP has often been described as a rare subtype of PV; however, accumulating evidence indicates that GPP is distinct from PV and associated with inpatient burden and systemic comorbidities, 3,24 consistent with our observations, GPP exhibited longer hospital stays and higher incidence of comorbidities than PV. As a biomarker conjugates innate and adaptive immune system, 25 significantly elevated NLR in GPP patients compared to PV may be a manifestation of pathogenesis distinction:…”

Health-Related Quality of Life and Economic Burden Among Hospitalized Children with Hand, Foot, and Mouth Disease: A Multiregional Study in China

“…Compared with the studies that included inpatients with worse conditions [ 4 , 10 , 20 ], in our study, lower average hospitalization and total costs were reported. However, the costs of patients in this study were higher than the outpatient costs calculated in previous studies [ 11 , 12 ]. The costs of hospitalization in our study were similar to those of general inpatients (3312–5520 CNY) after being adjusted to 2021 CNY [ 12 ].…”

“…Several studies have explored the economic burden of HFMD patients in China [4,[10][11][12]20]. Compared with the studies that included inpatients with worse conditions [4,10,20], in our study, lower average hospitalization and total costs were reported.…”

“…Previous studies have suggested that the patients with HFMD are more likely to report a worse health status and suffer a heavier economic burden than healthy children without HFMD in China [4,[8][9][10][11][12]. The three-level EuroQol-five dimensions (EQ-5D-3L) proxy 2 questionnaire [9] and TNO-AZL Preschool Quality of Life (TAPQOL) scale [10] were used to assess the health-related quality of life (HRQOL) of pediatric patients with HFMD.…”

“…However, few studies have used child-specific HRQOL instruments and compared health status changes before and after treatment. In terms of economic burden in China, previous studies focused on high-income provinces (i.e., Jiangsu and Guangzhou) and mainly focused on severe patients [4,[8][9][10][11][12]. In addition, cost data were collected almost 10 years ago [4,9].…”